Immuneering $(IMRX)$ reported a Q4 2025 net loss attributable to common stockholders of USD 11.6 million, or USD 0.18 per share, and FY 2025 net loss attributable to common stockholders of USD 56.0 million, or USD 1.27 per share. Q4 2025 R&D expenses were USD 9.3 million and G&A expenses were USD 4.5 million, while FY 2025 R&D expenses were USD 42.0 million and G&A expenses were USD 17.3 million. Cash, cash equivalents and marketable securities totaled USD 217.0 million at Dec. 31, 2025, with the company guiding that its cash runway is expected to fund operations into 2029. On the business side, Immuneering highlighted updated Phase 2a data for atebimetinib plus modified gemcitabine and nab-paclitaxel (mGnP) in first-line pancreatic cancer (N=34; 13.4 months median follow-up), reporting 64% overall survival at 12 months (as of a Dec. 15, 2025 data cutoff). The company said it is on track to report updated survival data from over 50 patients in H1 2026 and updated circulating tumor DNA data in Q2 2026, and reiterated plans to dose the first patient in its pivotal Phase 3 MAPKeeper 301 trial in mid-2026. Immuneering also expects dosing to begin in a Phase 2 trial of atebimetinib plus Libtayo in first-line RAS-mutant non-small cell lung cancer in H2 2026, and noted it was added to the Nasdaq Biotechnology Index in December 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.